文献速递神经肿瘤脊柱脊髓外科

脊柱转移瘤的立体定向体部放疗:24 Gy分2次每日照射综述

Stereotactic body radiotherapy for spine metastases: a review of 24 Gy in 2 daily fractions.
PubMed 文献 · J Neurooncol · 2023-05-08

本文综述了多伦多大学开发并在国际2/3期随机对照试验中验证的24 Gy分2次脊柱立体定向体部放疗方案。文献显示1年局部控制率为83-93.9%,1年椎体压缩性骨折率为5.4-22%,再程放疗1年局部控制率为72-86%,术后1年局部控制率为70-84%。作者认为该方案是开展脊柱立体定向体部放疗项目的理想起点。

要点

  • 24 Gy分2次方案有1级证据支持,在降低毒性与兼顾患者便利性和经济负担间取得良好平衡。
  • 文献报道1年局部控制率为83-93.9%,1年椎体压缩性骨折率为5.4-22%。
  • 再程放疗1年局部控制率为72-86%,术后1年局部控制率为70-84%。

核心结论

  • 24 Gy分2次剂量分割方案得到已发表文献的充分支持,是希望建立脊柱立体定向体部放疗项目的中心理想的起点。

研究设计与样本

  • 本文为综述,概述了多伦多大学开发并在国际2/3期随机对照试验中测试的24 Gy分2次脊柱立体定向体部放疗方案。

主要发现

  • 文献汇总全球经验显示,24 Gy分2次方案的1年局部控制率为83-93.9%,1年椎体压缩性骨折率为5.4-22%。
  • 对既往常规外照射放疗失败的脊柱转移瘤进行24 Gy分2次再程放疗可行,1年局部控制率为72-86%。
  • 术后脊柱立体定向体部放疗数据有限,但支持使用24 Gy分2次,报道的1年局部控制率为70-84%。
  • 在随访成熟的系列中, plexopathy、radiculopathy和myositis发生率通常低于5%;当脊髓避让结构限制为2次17 Gy时,de novo设置中未报告放射性脊髓病病例。
  • 再程放疗后已观察到放射性脊髓病;近期报道了2次28 Gy的剂量递增并采用更严格的 critical neural tissues 剂量约束,提示局部控制率改善。

关键数值与推荐

  • 24 Gy分2次方案中,脊髓避让结构限制为2次17 Gy时,de novo设置未报告放射性脊髓病。
  • 1年局部控制率范围83-93.9%,1年椎体压缩性骨折率范围5.4-22%。
  • 再程放疗1年局部控制率范围72-86%;术后1年局部控制率范围70-84%。
  • 在随访成熟的系列中,plexopathy、radiculopathy和myositis发生率通常低于5%。
  • 2次28 Gy剂量递增方案采用更高的 critical neural tissues 剂量约束,提示局部控制率改善。

临床怎么用

  • 作者认为,2次28 Gy剂量递增方案可能对放疗抗拒组织学、高级别硬膜外病变和/或椎旁病变的患者重要。
  • 作者认为,24 Gy分2次方案是希望建立脊柱立体定向体部放疗项目的中心理想的起点。
  • 再程放疗放射性脊髓病已在2次立体定向体部放疗后观察到。

局限性

  • 术后脊柱立体定向体部放疗数据有限。
  • 再程放疗后已观察到放射性脊髓病。
  • 在de novo设置中,当脊髓避让结构限制为2次17 Gy时,未报告放射性脊髓病病例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Stereotactic body radiotherapy (SBRT) has proven to be a highly effective treatment for selected patients with spinal metastases. Randomized evidence shows improvements in complete pain response rates and local control with lower retreatment rates favoring SBRT, compared to conventional external beam radiotherapy (cEBRT). While there are several reported dose-fractionation schemes for spine SBRT, 24 Gy in 2 fractions has emerged with Level 1 evidence providing an excellent balance between minimizing treatment toxicity while respecting patient convenience and financial strain. METHODS: We provide an overview of the 24 Gy in 2 SBRT fraction regimen for spine metastases, which was developed at the University of Toronto and tested in an international Phase 2/3 randomized controlled trial. RESULTS: The literature summarizing global experience with 24 Gy in 2 SBRT fractions suggests 1-year local control rates ranging from 83-93.9%, and 1-year rates of vertebral compression fracture ranging from 5.4-22%. Reirradiation of spine metastases that failed prior cEBRT is also feasible with 24 Gy in 2 fractions, and 1-year local control rates range from 72-86%. Post-operative spine SBRT data are limited but do support the use of 24 Gy in 2 fractions with reported 1-year local control rates ranging from 70-84%. Typically, the rates of plexopathy, radiculopathy and myositis are under 5% in those series reporting mature follow up, with no cases of radiation myelopathy (RM) reported in the de novo setting when the spinal cord avoidance structure is limited to 17 Gy in 2 fractions. However, re-irradiation RM has been observed following 2 fraction SBRT. More recently, 2-fraction dose escalation with 28 Gy, with a higher dose constraint to the critical neural tissues, has been reported suggesting improved rates of local control. This regimen may be important in those patients with radioresistant histologies, high grade epidural disease, and/or paraspinal disease. CONCLUSION: The dose-fractionation of 24 Gy in 2 fractions is well-supported by published literature and is an ideal starting point for centers looking to establish a spine SBRT program.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Nguyen EK, Ruschin M, Zhang B, et al. Stereotactic body radiotherapy for spine metastases: a review of 24 Gy in 2 daily fractions. J Neurooncol. 2023. PMID: 37155133. doi:10.1007/s11060-023-04327-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。